🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsVendor ReviewsFirst time ordering compounded - what do I even look for?? — anyone have experience?

First time ordering compounded - what do I even look for?? — anyone have experience?

JakeBK_lifts Sat, Oct 19, 2024 at 6:24 AM 37 replies 2,114 viewsPage 1 of 8
This thread is more than 19 months old. Information may be outdated. Consider searching for more recent discussions.
JakeBK_lifts
Member
523
2,345
Jul 2024
Brooklyn, NY
Oct 19, 2024 at 6:24 AM#1

This gets cited here weekly, usually second-hand, so it is worth setting out what it does and does not establish.

They are two different exemptions from the same federal requirements and they buy different things. A 503A pharmacy is regulated primarily by the state board, needs a patient-specific prescription, is exempt from CGMP, and may use a bulk substance that has a USP monograph, is a component of an approved drug, or appears on the 503A bulks list — three independent doorways. A 503B outsourcing facility registers with the FDA, is inspected on a risk basis, must comply with CGMP, may compound for office stock without a patient-specific prescription, and has one doorway to a permitted bulk substance: the 503B bulks list, or the drug shortage list.

Where I think it is weakest: the comparator does most of the work in how this gets reported, and it is not the comparator most people think they are citing.

The narrow version of the question is what actually distinguishes 503A from 503B, in terms of what each may make and from what starting material. Tell me what I have not thought of.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
23 18TrialTracker_MD, JennaRN, LabKate and 20 others
Reply Quote Save Share Report
SarahChen_PharmD
VIP Member
4,567
22,341
Dec 2023
San Diego, CA
Oct 19, 2024 at 6:29 AM#2
JakeBK_lifts said:
They are two different exemptions from the same federal requirements and they buy different things.

JakeBK_lifts has the substance of this right. The condition it depends on is worth stating. Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists. For 503B the shortage clause was the only route to these molecules, so that route shut completely. A 503A pharmacy can still argue a doorway via "component of an approved drug" — but only for the substance in the form present in the approved product, which is exactly where the base-versus-salt argument lives, and it does nothing about the copy restriction, which came back into force on resolution.

22 17NurseKim_ATL, paul_denver, TinaHashiRN and 19 others
Reply Quote Save Share Report
labquiet_amy
Senior Member
1,234
6,789
Mar 2024
Cambridge, MA
Oct 19, 2024 at 6:34 AM#3
JakeBK_lifts said:
They are two different exemptions from the same federal requirements and they buy different things.

Pushing back on JakeBK_lifts here. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.

21 16LibrarianMeg, bri_stats, pete_manc_UK and 18 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
PharmacoVig_BOS
Senior Member
1,567
8,901
Feb 2024
Boston, MA
Oct 19, 2024 at 6:39 AM#4

Answering the narrow version, because the broad one does not have a single answer. The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.

20 15kate.chem, DataDave, Dr.GutHealth and 17 others
Reply Quote Save Share Report
roxy_nash
Member
178
890
Dec 2024
Nashville, TN
Oct 19, 2024 at 7:05 AM#5
SarahChen_PharmD said:
Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.

Mine went the same way, slower. Posting only so the count is not one.

19 14kim_atl_prep, sarah_TO, wendy_avl and 16 others
Reply Quote Save Share Report
1238

Similar Threads

[REVIEW] WWB — 8 months, 6 orders, all Janoshik tested7 replies
[REVIEW] QSC — consistency and pricing, 10+ orders deep5 replies
[REVIEW] GGPeps — 6 orders, all independently tested3 replies
Which vendor should I go with? Side-by-side comparison3 replies
How do you vet a new vendor? My quality checklist9 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register